Procter & Gamble Health share price
NSE: PGHLBSE: 500126Pharmaceuticals & BiotechnologySmall Cap
Procter & Gamble Health Limited · Formerly Merck · Face value ₹10 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Jan 1982 on BSE, Apr 1996 on NSE
Last close ₹5,513.50up ₹114.50 (2.12%)BSE ₹5,510.60
Share price at the NSE close on 29 Oct 2026. Previous close ₹5,399.00.
29 Oct: open ₹5,399.00, high ₹5,540.00, low ₹5,380.50
52-week range of traded prices to 29 Oct 2026
₹4,707.00Low, 6 Apr 2026₹6,975.00High, 15 Jul 2026
- Next results date: the board meets on 2 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹9,152 Cr585th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 25.64
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 17.45
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 3.72%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 67.2%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 84.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 5,66357.6% delivered
Results
Standalone; ₹ crore.Procter & Gamble Health quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹364 Crdown 1.82%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹96 Crup 1.64%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 26.4%
Revenue by quarter
Peak revenue ₹374 Cr, quarter to Dec 2025; lowest ₹310 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 313 | 310 | – | 339 | 325 | 374 | 370 | 364 |
| Net profit | 82 | 91 | – | 66 | 89 | 78 | 95 | 96 |
| Net margin | 26.3% | 29.3% | – | 19.5% | 27.2% | 20.8% | 25.5% | 26.4% |
Standalone. The last eight quarters. The latest is shaded. No results on record for the quarter to Mar 2025.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,408 Crup 50.72%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹327 Crup 39.46%
- Net margin
- 23.2%
Revenue by year
Net profit by year, a loss in red
The company moved its year end from December to June: its last year to December on record ended in Dec 2018, its first year to June in Jun 2021. The company moved its year end from June to March: its last year to June on record ended in Jun 2024, its first year to March in Mar 2025.
The years either side of a change of basis do not compare. From the year to Dec 2018, the company's revenue for that year, ₹849 Cr, differs from its quarters added, ₹952 Cr; the company reports a discontinued business.
| ₹ crore | Dec 2016 | Dec 2017 | Dec 2018 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 996 | 1,119 | 849 | – | 1,009 | 1,114 | 1,230 | 1,151 | 934 | 1,408 |
| Net profit | 76 | 94 | 839 | – | 177 | 193 | 229 | 201 | 234 | 327 |
| Net margin | 7.6% | 8.4% | – | – | 17.5% | 17.3% | 18.7% | 17.5% | 25.1% | 23.2% |
Standalone. Years to December, then June, then March. The latest is shaded. No results on record for the year to Jun 2020. Net margin is left blank for Dec 2018: the profit includes the result of a business the company has discontinued, which the revenue does not, so the two make no margin.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceuticals, which carries all its revenue.
Valuation
Today, against the company's own history. Its history crosses a change of basis in the accounts in the year to Dec 2018: days before it are of the company before the change.Procter & Gamble Health PE ratio and valuation
Price to earnings
At or below today's level on 14% of 2,258 trading days over the last 10 years.
LowestHighest
Its median39.50Industry median28.38
Price to book
At or below today's level on 91% of 1,840 trading days since Aug 2018.
LowestHighest
Its median11.73Industry median2.99
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 65% of 2,455 trading days over the last 10 years.
LowestHighest
Its median2.59%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | −2.5% | +39.5% | −33.1% | 4.3% |
| 3 years | +4.9% | – | – | 4.1% |
| 5 years | −1.9% | – | – | 3.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add. Earnings growth and the change in P/E are left empty where earnings per share at either end of the window was a loss or is not on record.
Mutual fund holdings
29 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 3 of the 8 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.All 29 funds holding Procter & Gamble Health
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 2
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 4
- AddedAdded. Funds that held more shares than at the end of the month before.
- 6
- CutCut. Funds that held fewer shares than at the end of the month before.
- 2
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 15
| Fund | |||
|---|---|---|---|
 Nippon India Small Cap FundNippon India Mutual Fund | 6,94,659 | 0.48% | ₹386.4 Cr |
 UTI MNC FundUTI Mutual Fund | 1,89,876 | 4.03% | ₹105.6 Cr |
 DSP Healthcare FundDSP Mutual Fund | 1,59,288 | 2.36% | ₹88.6 Cr |
 Aditya Birla Sun Life MNC FundAditya Birla Sun Life Mutual Fund | 94,716 | 1.74% | ₹52.7 Cr |
 Tata India Pharma & Healthcare FundTata Mutual Fund | 74,596 | 2.75% | ₹41.5 Cr |
| UTI Healthcare FundUTI Mutual Fund | 50,000 | 1.95% | ₹27.8 Cr |
| Aditya Birla Sun Life Consumption FundAditya Birla Sun Life Mutual Fund | 44,504 | 0.43% | ₹24.8 Cr |
 Bajaj Finserv Small Cap FundBajaj Finserv Mutual Fund | 36,120 | 0.73% | ₹20.1 Cr |
| Aditya Birla Sun Life Pharma and Healthcare FundAditya Birla Sun Life Mutual Fund | 35,195 | 1.82% | ₹19.6 Cr |
| Aditya Birla Sun Life Business Cycle FundAditya Birla Sun Life Mutual Fund | 28,381 | 0.92% | ₹15.8 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Procter & Gamble Health competitors and peers
Pharmaceuticals, 215 listed companies, priced on 29 Oct 2026. The table lists the 8 companies closest to Procter & Gamble Health in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Akums Drugs and PharmaceuticalsAKUMS | 11,664 | 39.98 | 3.52 | +9.2% | −14.6% | 9.2% | 12.0% | 0.40% |
 Strides Pharma ScienceSTAR | 10,116 | 16.49 | 3.26 | +7.3% | – | 21.7% | 15.1% | 0.46% |
 Viyash ScientificVIYASH | 9,917 | – | 3.41 | +96.5% | – | – | 11.2% | 0.00% |
 Blue Jet HealthcareBLUEJET | 9,531 | 40.57 | – | −27.5% | −34.5% | 18.8% | 18.1% | 0.24% |
 Aarti PharmalabsAARTIPHARM | 8,412 | – | 3.73 | +13.4% | – | – | 11.9% | 0.38% |
 Symbiotec PharmalabSYMBIOTEC | 8,033 | – | – | – | – | – | – | 0.00% |
 Sanofi Consumer Healthcare IndiaSANOFICONR | 7,987 | 28.56 | 22.96 | +22.7% | +28.4% | 92.5% | 102.5% | 2.16% |
 Sanofi IndiaSANOFI | 7,346 | 20.15 | 8.89 | −5.7% | +2.3% | 45.3% | 57.3% | 3.86% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Procter & Gamble Health dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹440.00 a share, year to Dec 2018.
| Ex-date | Type | Per share |
|---|---|---|
| 27 Aug 2026 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. Final dividend in the glossary | ₹45.00 |
| 12 Feb 2026 | Interim | ₹110.00 |
| 12 Feb 2026 | Special | ₹50.00 |
| 22 Aug 2025 | Final | ₹45.00 |
| 21 Feb 2025 | Interim | ₹80.00 |
| 28 Nov 2024 | Final | ₹60.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Procter & Gamble Health announcements
Sep 2026
30 Sep · Board meeting
3 Sep · Meeting
Procter & Gamble Health share price by year
Each calendar year to 2025.Procter & Gamble Health share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 5,703.00 | +8.9% | 6,581.50 | 5,002.60 |
| 2024 | 5,238.05 | +5.9% | 5,770.60 | 4,662.40 |
| 2023 | 4,947.75 | +25.2% | 5,448.95 | 4,001.75 |
| 2022 | 3,953.00 | −26.0% | 5,251.50 | 3,938.00 |
| 2021 | 5,338.40 | −21.7% | 7,430.60 | 4,959.60 |
| 2020 | 6,817.50 | +56.1% | 7,110.75 | 3,110.00 |
| 2019 | 4,366.70 | +41.8% | 4,921.75 | 2,903.90 |
| 2018 | 3,078.70 | +138.7% | 3,512.05 | 1,305.30 |
| 2017 | 1,289.75 | +29.1% | 1,315.10 | 935.95 |
| 2016 | 999.30 | +28.7% | 1,039.15 | 630.60 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 28 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 28 Oct 2026 | 5,475.00 | 5,475.00 | 5,346.50 | 5,399.00 | 5,398.92 | 6,327 | 55.2% |
| 27 Oct 2026 | 5,070.00 | 5,591.00 | 5,043.00 | 5,489.00 | 5,393.34 | 26,194 | 64.8% |
| 26 Oct 2026 | 5,015.00 | 5,136.00 | 4,922.00 | 5,056.00 | 5,062.99 | 9,287 | 49.3% |
| 23 Oct 2026 | 5,059.00 | 5,077.00 | 4,735.00 | 5,015.00 | 4,963.75 | 18,321 | 48.9% |
| 22 Oct 2026 | 5,015.00 | 5,093.00 | 4,978.00 | 5,062.50 | 5,027.66 | 8,364 | 58.4% |
| 21 Oct 2026 | 5,135.50 | 5,148.00 | 4,997.00 | 5,048.00 | 5,046.00 | 6,542 | 62.9% |
| 19 Oct 2026 | 5,204.50 | 5,211.50 | 5,105.50 | 5,135.50 | 5,151.19 | 5,453 | 59.3% |
| 16 Oct 2026 | 5,158.00 | 5,229.00 | 5,112.50 | 5,200.00 | 5,188.69 | 8,465 | 58.2% |
| 15 Oct 2026 | 5,258.50 | 5,259.00 | 5,122.50 | 5,149.00 | 5,168.96 | 8,366 | 62.9% |
Prices in ₹ per share as traded, not adjusted.
Company details
- NSE symbol
- PGHL
- BSE code
- 500126
- ISIN
- INE199A01012
- Industry
- Pharmaceuticals & Biotechnology
- Former symbols
- MERCK, EMERCK
- Website
- www.pghealthindia.com
- CIN
- L99999MH1967PLC013726
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1967
- Registered office
- P&G Plaza, Cardinal Gracias Road, Chakala, Andheri (E), Mumbai 400009, Maharashtra
- Share registrar
- KFin Technologies Ltd
- Keeps the register of shareholders and handles transfers and dividend payments